Placeholder Banner

BIO Files Amicus Brief Urging Supreme Court Review of Patent-Related False Claims Act Case

May 9, 2024

BIO filed an amicus brief supporting Supreme Court review of a patent case involving the public disclosure bar of the False Claims Act (FCA). The brief argues that the 9th Circuit erred when it held that an administrative patent challenge proceeding in the Patent Trial and Appeal Board (PTAB) is not “publicly disclosed” for purposes of the FCA because (1) the government is not a “party” to an inter partes review (IPR), and (2) an IPR proceeding is not sufficiently “investigative” to be a “hearing.” BIO believes that this decision is wrong and must be corrected, because otherwise relators could bring FCA claims based only on their “insights” from publicly-available information in the PTAB record, without otherwise contributing any new or non-public information.

Related Resources
BIO Files Amicus Brief Urging Supreme Court Review of Patent-Related False Claims Act Case
Discover More
BIO filed an amicus brief in the Supreme Court of the State of California, encouraging its review of the lower court decision in the Gilead Tenofovir Cases.The Court of Appeal decision operates from a misunderstanding of the drug development and FDA…
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…
BIO filed an amicus brief in the U.S. Court of Appeals for the Sixth Circuit, seeking the reversal of a lower court's ruling that would set aside the 2022 rescission of the Securities and Exchange Commission (SEC) 2020 Rule regulating proxy advisory…